Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis
about
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaThe changing epidemiology of Staphylococcus aureus?A comparison of different antibiotic regimens for the treatment of infective endocarditisAntibiotics for bacteraemia due to Staphylococcus aureusPotential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureusLysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.Detection of Staphylococcus aureus delta-toxin production by whole-cell MALDI-TOF mass spectrometryAcute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.Methicillin-Resistant Staphylococcus aureus Infections.A comparison of clinical features and mortality among methicillin-resistant and methicillin-sensitive strains of Staphylococcus aureus endocarditis.Comparison of the clinical features and outcomes of infective endocarditis between hemodialysis and non-hemodialysis patients.Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureusTeicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureusBactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Increased neutrophil extracellular trap-mediated Staphylococcus aureus clearance through inhibition of nuclease activity by clindamycin and immunoglobulinShort-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolatesCerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit.Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized studyClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Clinical management of Staphylococcus aureus bacteremia: a review.The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia.Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates.Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremiaVancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.An interventional program to improve antibiotic use.Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.Ampicillin-sulbactam is effective in prevention and therapy of experimental endocarditis caused by beta-lactamase-producing coagulase-negative staphylococci.Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureusPharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faeciumPharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus - a retrospective cohort studyTests for bactericidal effects of antimicrobial agents: technical performance and clinical relevanceStaphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.
P2860
Q22241905-44D8B236-F36A-4CA5-8E38-EBB7BA489E50Q22305657-133F6B9B-00C9-4688-B950-A11FBB9FA355Q24185887-B3FAF261-B0A7-43CD-98E7-68ACA62F4898Q24186950-1C55C511-EE8D-4197-AF7C-DD149ACB8EEFQ27027412-3F13E896-1587-4D5F-9050-FD88C28090C9Q28379547-74770858-A726-4C83-B649-FD5991566A15Q28727420-60370699-C162-4C06-BF1D-A5DC4C13FF42Q30251580-0A419CCF-63D9-49FA-86F4-4CBB94099579Q30306476-BDAEE877-A560-4CF2-A0FC-47D4E556DB25Q33628238-84A4C840-31F5-4547-A8DB-0271BB478B06Q33739826-EE6275E4-B004-412B-925F-94DADB3BC991Q33750776-EF8F51DE-96B4-4BFE-ADE9-F829EA7C92E5Q33754412-63F1416C-5FB8-43E7-85D3-32744022783CQ33756241-D89A6F07-9F82-4AC2-8C11-C6939FA2B8CCQ33758399-21359B88-5082-41B4-912C-5040494D6EFBQ33880228-19FF90EA-F8D4-4B9F-8675-24ECC5984252Q33883648-C696830A-64F5-4B71-84FB-E8599557EA7DQ33977223-4713449B-8F3A-491A-903A-29881534A661Q33978642-FF1838C9-2163-491B-AFF5-A788E0281252Q33979524-63F22A50-C2C7-4C34-B050-4E3C20CEB34FQ33982863-D60B3AD6-22BA-4154-9E13-47A3F8F48208Q34157657-80A3DAD1-C675-423B-9640-49FCA368BCDFQ34441035-6B287788-2839-4991-B3D3-AC76395660A4Q34447860-5DAA68C3-8432-4124-A8FE-C8C1EF00FF06Q34510414-1B915F6C-EAC6-409C-94ED-BEACD9B7BE01Q34529085-7E588135-DE86-410E-95A3-E89010196FC9Q34783668-CD0EE059-90C4-4163-929E-43C45B71BD97Q34885043-1D84161B-1D37-4B20-A60B-02A7BEEBB4D9Q35030135-5186B7E9-B43F-48F6-BFD7-BC9442B7B70BQ35112370-D8690C37-CD00-456C-B87E-AE29F8039768Q35116133-66C1561F-5D16-4D3B-AAF2-E50C91DA27CBQ35121661-40C50ABB-A0FF-4C16-B863-FFF9D2335134Q35123155-D59EFA61-6804-43F9-96D6-EFA9B27F16B1Q35125203-DBA6B1A4-0EFF-4020-BA01-00C7BF8DAB00Q35136634-8365CC2D-23F3-4BB6-BE6A-D68B044E508DQ35138989-B3EFFF5E-CA5D-4B3C-8BD9-0F21A9A05B0DQ35376362-6932561F-850B-471F-B3E4-6BE9889C24E5Q35391386-0C7071D1-1EB5-4B1E-86C7-9874E8B15B67Q35474824-DCABD322-D97F-42A5-BCA4-1AF3FA55DA03Q35541702-C5914730-7446-42EB-9FA6-65ACB65C1213
P2860
Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis
description
1991 nî lūn-bûn
@nan
1991 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@ast
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@en
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@nl
type
label
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@ast
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@en
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@nl
prefLabel
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@ast
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@en
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@nl
P2093
P1476
Slow response to vancomycin or ...... hylococcus aureus endocarditis
@en
P2093
P304
P356
10.7326/0003-4819-115-9-674
P407
P577
1991-11-01T00:00:00Z